Pfizer Net Debt from 2010 to 2026

PFE Stock

USD 27.22 0.73 2.76%

Pfizer's Net Debt is increasing over the years with slightly volatile fluctuation. Overall, Net Debt is expected to go to about 79.6 B this year. Net Debt is the total debt of Pfizer Inc minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. View All Fundamentals

Net Debt

First Reported

1985-12-31

Previous Quarter

60.2 B

Current Value

60.4 B

Quarterly Volatility

20.3 B

Black Monday

Oil Shock

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Interest Hikes

Check Pfizer financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pfizer's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.8 B, Interest Expense of 2.8 B or Total Revenue of 40.3 B, as well as many indicators such as Price To Sales Ratio of 4.38, Dividend Yield of 0.0725 or PTB Ratio of 1.44. Pfizer financial statements analysis is a perfect complement when working with Pfizer Valuation or Volatility modules.

Build AI portfolio with Pfizer Stock

Check out the analysis of Pfizer Correlation against competitors.

Analyzing Pfizer's Net Debt over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Debt has evolved provides context for assessing Pfizer's current valuation and future prospects.

Latest Pfizer's Net Debt Growth Pattern

Below is the plot of the Net Debt of Pfizer Inc over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. Pfizer's Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pfizer's overall financial position and show how it may be relating to other accounts over time.

Net Debt

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Net Debt

Timeline

Pfizer Net Debt Regression Statistics

	Arithmetic Mean	43,385,407,353
	Geometric Mean	30,395,628,316
	Coefficient Of Variation	46.19
	Mean Deviation	15,003,304,498
	Median	36,490,000,000
	Standard Deviation	20,039,348,108
	Sample Variance	401575472.6T
	Range	79.5B
	R-Value	0.83
	Mean Square Error	132798319.6T
	R-Squared	0.69
	Significance	0.000036
	Slope	3,296,326,225
	Total Sum of Squares	6425207561.3T

Pfizer Net Debt History

	2026	79.6 B
	2025	75.8 B
	2024	66 B
	2023	72.2 B
	2022	34.5 B
	2021	35.1 B
	2020	36.5 B

Other Fundumenentals of Pfizer Inc

Net Debt To E B I T D A

Pfizer Net Debt component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Property Plant Equipment	Accounts Payable	Short Term Investments	Capital Stock	Common Stock	Long Term Debt	Good Will	Treasury Stock	Current Deferred Revenue	Net Tangible Assets	Total Permanent Equity	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Cash And Equivalents	Net Invested Capital	Net Working Capital
Total Assets		0.77	0.86	0.82	0.6	-0.13	0.63	0.34	0.9	0.95	0.85	0.42	0.9	0.9	0.9	0.79	-0.61	-0.08	0.57	0.53	0.33	0.63	-0.38	-0.32	0.24	-0.34	0.58	-0.28
Total Stockholder Equity	0.77		0.48	0.57	0.76	0.31	0.86	0.22	0.63	0.64	0.65	0.52	0.83	0.83	0.55	0.8	-0.51	0.08	0.4	0.34	0.22	0.47	-0.26	-0.03	0.01	-0.26	0.43	-0.14
Net Debt	0.86	0.48		0.85	0.37	-0.33	0.24	0.46	0.84	0.91	0.82	0.04	0.72	0.72	0.98	0.76	-0.66	-0.27	0.62	0.63	0.64	0.77	-0.55	-0.47	0.52	-0.4	0.75	-0.52
Retained Earnings	0.82	0.57	0.85		0.37	-0.23	0.32	0.27	0.63	0.84	0.95	0.16	0.79	0.79	0.86	0.75	-0.89	-0.23	0.76	0.67	0.45	0.9	-0.72	-0.24	0.34	-0.66	0.61	-0.33
Net Receivables	0.6	0.76	0.37	0.37		0.18	0.69	0.1	0.5	0.59	0.51	0.38	0.66	0.66	0.43	0.64	-0.3	0.17	0.25	0.59	0.16	0.34	-0.25	-0.14	0.01	-0.27	0.25	0.02
Total Liab	-0.13	0.31	-0.33	-0.23	0.18		0.27	0.19	-0.15	-0.32	-0.14	0.04	0.04	0.04	-0.34	0.11	-0.09	0.53	-0.37	-0.15	-0.38	-0.34	0.24	0.45	-0.02	0.29	-0.41	0.03
Total Current Assets	0.63	0.86	0.24	0.32	0.69	0.27		0.05	0.44	0.47	0.38	0.81	0.72	0.72	0.34	0.56	-0.24	0.19	0.17	0.07	-0.05	0.19	0.02	-0.01	-0.23	-0.04	0.15	0.25
Short Term Debt	0.34	0.22	0.46	0.27	0.1	0.19	0.05		0.44	0.26	0.23	-0.23	0.44	0.44	0.3	0.59	-0.38	0.36	-0.29	0.18	0.09	0.25	0.0	-0.14	0.86	-0.11	0.18	-0.55
Intangible Assets	0.9	0.63	0.84	0.63	0.5	-0.15	0.44	0.44		0.88	0.72	0.22	0.73	0.73	0.84	0.72	-0.38	-0.13	0.39	0.48	0.41	0.47	-0.21	-0.53	0.37	-0.18	0.64	-0.38
Property Plant Equipment	0.95	0.64	0.91	0.84	0.59	-0.32	0.47	0.26	0.88		0.86	0.27	0.81	0.81	0.96	0.75	-0.58	-0.23	0.67	0.64	0.49	0.7	-0.51	-0.46	0.25	-0.44	0.68	-0.3
Accounts Payable	0.85	0.65	0.82	0.95	0.51	-0.14	0.38	0.23	0.72	0.86		0.18	0.78	0.78	0.84	0.76	-0.82	-0.24	0.74	0.75	0.44	0.83	-0.68	-0.3	0.32	-0.57	0.62	-0.28
Short Term Investments	0.42	0.52	0.04	0.16	0.38	0.04	0.81	-0.23	0.22	0.27	0.18		0.44	0.44	0.15	0.16	-0.03	-0.02	0.11	-0.18	-0.27	0.0	0.2	0.01	-0.46	0.03	-0.02	0.47
Capital Stock	0.9	0.83	0.72	0.79	0.66	0.04	0.72	0.44	0.73	0.81	0.78	0.44		1.0	0.74	0.9	-0.73	0.21	0.4	0.51	0.19	0.67	-0.34	-0.17	0.27	-0.4	0.39	-0.16
Common Stock	0.9	0.83	0.72	0.79	0.66	0.04	0.72	0.44	0.73	0.81	0.78	0.44	1.0		0.74	0.9	-0.73	0.21	0.4	0.51	0.19	0.67	-0.34	-0.17	0.27	-0.4	0.39	-0.16
Long Term Debt	0.9	0.55	0.98	0.86	0.43	-0.34	0.34	0.3	0.84	0.96	0.84	0.15	0.74	0.74		0.75	-0.63	-0.3	0.71	0.62	0.64	0.76	-0.57	-0.43	0.35	-0.38	0.75	-0.43
Good Will	0.79	0.8	0.76	0.75	0.64	0.11	0.56	0.59	0.72	0.75	0.76	0.16	0.9	0.9	0.75		-0.75	0.1	0.38	0.58	0.47	0.76	-0.44	-0.27	0.48	-0.42	0.58	-0.34
Treasury Stock	-0.61	-0.51	-0.66	-0.89	-0.3	-0.09	-0.24	-0.38	-0.38	-0.58	-0.82	-0.03	-0.73	-0.73	-0.63	-0.75		-0.02	-0.56	-0.62	-0.3	-0.84	0.67	0.03	-0.43	0.61	-0.36	0.28
Current Deferred Revenue	-0.08	0.08	-0.27	-0.23	0.17	0.53	0.19	0.36	-0.13	-0.23	-0.24	-0.02	0.21	0.21	-0.3	0.1	-0.02		-0.62	-0.04	-0.63	-0.33	0.31	0.33	0.15	0.17	-0.69	0.12
Net Tangible Assets	0.57	0.4	0.62	0.76	0.25	-0.37	0.17	-0.29	0.39	0.67	0.74	0.11	0.4	0.4	0.71	0.38	-0.56	-0.62		0.48	0.64	0.73	-0.71	-0.12	-0.14	-0.44	0.7	-0.23
Total Permanent Equity	0.53	0.34	0.63	0.67	0.59	-0.15	0.07	0.18	0.48	0.64	0.75	-0.18	0.51	0.51	0.62	0.58	-0.62	-0.04	0.48		0.4	0.65	-0.75	-0.38	0.46	-0.62	0.37	-0.22
Long Term Debt Total	0.33	0.22	0.64	0.45	0.16	-0.38	-0.05	0.09	0.41	0.49	0.44	-0.27	0.19	0.19	0.64	0.47	-0.3	-0.63	0.64	0.4		0.66	-0.55	-0.38	0.27	-0.22	0.9	-0.49
Capital Surpluse	0.63	0.47	0.77	0.9	0.34	-0.34	0.19	0.25	0.47	0.7	0.83	0.0	0.67	0.67	0.76	0.76	-0.84	-0.33	0.73	0.65	0.66		-0.74	-0.28	0.37	-0.67	0.71	-0.3
Deferred Long Term Liab	-0.38	-0.26	-0.55	-0.72	-0.25	0.24	0.02	0.0	-0.21	-0.51	-0.68	0.2	-0.34	-0.34	-0.57	-0.44	0.67	0.31	-0.71	-0.75	-0.55	-0.74		0.2	-0.29	0.74	-0.47	0.25
Long Term Investments	-0.32	-0.03	-0.47	-0.24	-0.14	0.45	-0.01	-0.14	-0.53	-0.46	-0.3	0.01	-0.17	-0.17	-0.43	-0.27	0.03	0.33	-0.12	-0.38	-0.38	-0.28	0.2		-0.3	0.37	-0.43	-0.14
Short Long Term Debt	0.24	0.01	0.52	0.34	0.01	-0.02	-0.23	0.86	0.37	0.25	0.32	-0.46	0.27	0.27	0.35	0.48	-0.43	0.15	-0.14	0.46	0.27	0.37	-0.29	-0.3		-0.31	0.26	-0.6
Cash And Equivalents	-0.34	-0.26	-0.4	-0.66	-0.27	0.29	-0.04	-0.11	-0.18	-0.44	-0.57	0.03	-0.4	-0.4	-0.38	-0.42	0.61	0.17	-0.44	-0.62	-0.22	-0.67	0.74	0.37	-0.31		-0.29	0.05
Net Invested Capital	0.58	0.43	0.75	0.61	0.25	-0.41	0.15	0.18	0.64	0.68	0.62	-0.02	0.39	0.39	0.75	0.58	-0.36	-0.69	0.7	0.37	0.9	0.71	-0.47	-0.43	0.26	-0.29		-0.5
Net Working Capital	-0.28	-0.14	-0.52	-0.33	0.02	0.03	0.25	-0.55	-0.38	-0.3	-0.28	0.47	-0.16	-0.16	-0.43	-0.34	0.28	0.12	-0.23	-0.22	-0.49	-0.3	0.25	-0.14	-0.6	0.05	-0.5

Click cells to compare fundamentals

About Pfizer Financial Statements

Pfizer stakeholders use historical fundamental indicators, such as Pfizer's Net Debt, to determine how well the company is positioned to perform in the future. Although Pfizer investors may analyze each financial statement separately, they are all interrelated. For example, changes in Pfizer's assets and liabilities are reflected in the revenues and expenses on Pfizer's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Pfizer Inc. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Net Debt	75.8 B	79.6 B
Net Debt To EBITDA	3.27	3.44

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

FSLY	Fastly Class A
MOB	Mobilicom Limited American
CMG	Chipotle Mexican Grill

When determining whether Pfizer Inc is a strong investment it is important to analyze Pfizer's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pfizer's future performance. For an informed investment choice regarding Pfizer Stock, refer to the following important reports:

How To Invest In Pfizer

Details

Is Pfizer Stock a good investment?

Details

What is Pfizer's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Pfizer Correlation against competitors.

You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Will Pharmaceuticals sector continue expanding? Could Pfizer diversify its offerings? Factors like these will boost the valuation of Pfizer. Anticipated expansion of Pfizer directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Pfizer data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.

Quarterly Earnings Growth

(0.21)

Dividend Share

1.72

Earnings Share

1.36

Revenue Per Share

11.012

Quarterly Revenue Growth

(0.01)

Investors evaluate Pfizer Inc using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Pfizer's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Pfizer's market price to deviate significantly from intrinsic value.

It's important to distinguish between Pfizer's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Pfizer should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Pfizer's market price signifies the transaction level at which participants voluntarily complete trades.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Pfizer Net Debt from 2010 to 2026

Latest Pfizer's Net Debt Growth Pattern

Pfizer Net Debt Regression Statistics

Pfizer Net Debt History

Other Fundumenentals of Pfizer Inc

Pfizer Net Debt component correlations

About Pfizer Financial Statements

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY